A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)
Clinical trial NCT01225731 · COMPLETED
Trial details
- NCT number
- NCT01225731
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-25
- Primary completion
- 2011-11-04
- Enrollment
- 355
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.